The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
The study is a prospective randomized, multi-center, double-blind, parallel, sham-controlled study, designed for comparison of two parallel groups, gammaCore®-Sapphire (active treatment) and a sham (inactive) treatment. The study period will begin with a four-week run-in period, during which there is no investigational treatment. The purpose of the run-in period will be to establish a baseline of the subject's headache/migraine history for longitudinal comparison. The run-in period will be followed by a 12-week randomized period when the subjects will be randomized (1:1) to either active treatment or sham (inactive) treatment. Subjects will dose themselves 3 times per day for 12 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
231
GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
Safety and effectiveness of gammaCore Sapphire as a treatment for the prevention of a migraine during the double-blind period measured by Incidence of Unexpected Adverse Events.
The primary outcome measurement for effectiveness is the difference between the active and sham treatment groups in the mean reduction in number of migraine days during the last 4 weeks of the 12-week double-blind period (versus during the 4-week run-in period).
Time frame: 12 weeks
Responder rate in the nVNS group compared to the sham group
A subject who reports at least a 50% decrease in the number of migraine days during the last 4 weeks in the 12-week double-blind period
Time frame: Last 4 weeks of the 12 week double-blind
Mean reduction in the number of headache days
Difference between the nVNS and sham treatment groups in mean reduction in the number of headache days during the last 4 weeks of the 12-week double-blind period
Time frame: Last 4 weeks of the 12 week double-blind
Mean reduction in days on which acute migraine medication
Difference between the nVNS and sham treatment groups in the mean reduction in days on which acute migraine medication was taken during the last 4 weeks of the 12 week double-blind period
Time frame: Last 4 weeks of the 12 week double-blind
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mayo Clinic
Scottsdale, Arizona, United States
The Research Center of Southern California
Carlsbad, California, United States
Stanford University Medical Center Hoover Pavilion
Palo Alto, California, United States
UCSF Headache Center
San Francisco, California, United States
California Medical Clinic for Headache
Santa Monica, California, United States
Summit Headache and Neurologic Institute, PC
Englewood, Colorado, United States
New England Institute for Neurology and Headache
Stamford, Connecticut, United States
Hartford HealthCare Headache Center
West Hartford, Connecticut, United States
University of Miami, Miller School of Medicine
Miami, Florida, United States
Diamond Headache Clinic
Chicago, Illinois, United States
...and 20 more locations